Solicitation of Written Comments on the Human Papillomavirus Working Group's Draft Report and Draft Recommendations for Improving Vaccination Rates in Adolescents for Consideration by the National Vaccine Advisory Committee, 18405-18406 [2015-07777]
Download as PDF
<![CDATA[
Federal Register / Vol. 80, No. 65 / Monday, April 6, 2015 / Notices
acquire or control voting securities or
assets of a company, including the
companies listed below, that engages
either directly or through a subsidiary or
other company, in a nonbanking activity
that is listed in section 225.28 of
Regulation Y (12 CFR 225.28) or that the
Board has determined by Order to be
closely related to banking and
permissible for bank holding
companies. Unless otherwise noted,
these activities will be conducted
throughout the United States.
Each notice is available for inspection
at the Federal Reserve Bank indicated.
The notice also will be available for
inspection at the offices of the Board of
Governors. Interested persons may
express their views in writing on the
question whether the proposal complies
with the standards of section 4 of the
BHC Act.
Unless otherwise noted, comments
regarding the applications must be
received at the Reserve Bank indicated
or the offices of the Board of Governors
not later than April 21, 2015.
A. Federal Reserve Bank of
Philadelphia (William Lang, Senior Vice
President) 100 North 6th Street,
Philadelphia, Pennsylvania 19105–
1521:
1. The Bancorp, Inc., Wilmington,
Delaware; to retain 49 percent of the
voting shares of Walnut Street 2014Issuer, LLC, Gladwyne, Pennsylvania,
and thereby engage in extending credit
and servicing loans, pursuant to section
225.28(b)(1).
Board of Governors of the Federal Reserve
System, April 1, 2015.
Michael J. Lewandowski,
Associate Secretary of the Board.
[FR Doc. 2015–07791 Filed 4–3–15; 8:45 am]
BILLING CODE 6210–01–P
GENERAL SERVICES
ADMINISTRATION
[Notice–MA–2015–01; Docket No. 2015–
0002, Sequence No. 5]
Federal Travel Regulation (FTR);
Relocation Allowances—Relocation
Income Tax (RIT) Allowance Tables
Office of Government-wide
Policy, U.S. General Services
Administration (GSA).
ACTION: Notice of a bulletin.
tkelley on DSK4VPTVN1PROD with NOTICES
AGENCY:
The purpose of this notice is
to inform agencies that FTR Bulletin 15–
03 pertaining to Relocation
Allowances—Relocation Income Tax
(RIT) Allowance Tables is now available
online at www.gsa.gov/ftrbulletin.
DATES: Effective: April 6, 2015.
SUMMARY:
VerDate Sep<11>2014
18:14 Apr 03, 2015
Jkt 235001
Mr.
Rick Miller, Office of Asset and
Transportation Management (MA),
Office of Government-wide Policy, GSA,
at 202–501–3822 or via email at
rodney.miller@gsa.gov. Please cite FTR
Bulletin 15–03.
SUPPLEMENTARY INFORMATION: The GSA
published FTR Amendment 2008–04 in
the Federal Register at 73 FR 35952 on
June 25, 2008, specifying that GSA
would no longer publish the RIT
Allowance tables in Title 41 of the Code
of Federal Regulation Part 302–17,
Appendices A through D; instead, the
tables would be available on a GSA Web
site. FTR Bulletin 15–03: Relocation
Allowances—Relocation Income Tax
(RIT) Allowance Tables is now available
and provides the annual changes to the
RIT allowance tables necessary for
calculating the amount of a transferee’s
increased tax burden due to his or her
official permanent change of station.
FTR Bulletin 15–03 and all other FTR
Bulletins can be found at www.gsa.gov/
ftrbulletin.
FOR FURTHER INFORMATION CONTACT:
Dated: March 30, 2015.
Giancarlo Brizzi,
Acting Associate Administrator, Office of
Government-wide Policy.
[FR Doc. 2015–07866 Filed 4–3–15; 8:45 am]
BILLING CODE 6820–14–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Eunice Kennedy Shriver National
Institute of Child Health and Human
Development; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in section 552b(c)(4)
and 552b(c)(6), title 5 U.S.C., as
amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Eunice Kennedy
Shriver National Institute of Child Health
and Human Development Special Emphasis
Panel; Academic-Community Partnership
Conference Series (R13).
Date: April 13, 2015.
Time: 9:00 a.m. to 6:00 p.m.
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
18405
Agenda: To review and evaluate grant
applications.
Place: Renaissance M Street Hotel, 1143
New Hampshire Avenue NW., Washington,
DC 20037.
Contact Person: Marita R. Hopmann, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Eunice Kennedy Shriver National
Institute of Child Health and Human
Development, NIH, 6100 Executive
Boulevard, Room 5B01, Bethesda, MD
20892–9304, (301) 435–6911, hopmannm@
mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment Program, National
Institutes of Health, HHS)
Dated: March 31, 2015.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–07741 Filed 4–3–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Solicitation of Written Comments on
the Human Papillomavirus Working
Group’s Draft Report and Draft
Recommendations for Improving
Vaccination Rates in Adolescents for
Consideration by the National Vaccine
Advisory Committee
National Vaccine Program
Office, Office of the Assistant Secretary
for Health, Office of the Secretary,
Department of Health and Human
Services.
ACTION: Notice.
AGENCY:
The National Vaccine
Advisory Committee (NVAC) was
established in 1987 to comply with Title
XXI of the Public Health Service Act
(Pub. L. 99–660) (§ 2105) (42 U.S. Code
300aa–5 (PDF—78 KB)). Its purpose is to
advise and make recommendations to
the Director of the National Vaccine
Program on matters related to program
responsibilities. The Assistant Secretary
for Health (ASH) has been designated by
the Secretary of Health and Human
Services (HHS) as the Director of the
National Vaccine Program. The National
Vaccine Program Office (NVPO) is
located within the Office of the
Assistant Secretary for Health (OASH),
Office of the Secretary, U.S. Department
of Health and Human Services (HHS).
NVPO provides leadership and fosters
collaboration among the various federal
SUMMARY:
E:\FR\FM\06APN1.SGM
06APN1
18406
Federal Register / Vol. 80, No. 65 / Monday, April 6, 2015 / Notices
agencies involved in vaccine and
immunization activities. The NVPO also
supports the National Vaccine Advisory
Committee (NVAC). The NVAC advises
and makes recommendations to the
ASH in her capacity as the Director of
National Vaccine Program on matters
related to vaccine program
responsibilities.
In February 2013, the NVAC created
a working group to review the current
state of HPV immunization, to
understand the root cause(s) for the
observed low vaccine uptake, both in
initiation and in series completion, and
to identify existing best practices to
increase the use of the HPV vaccine in
young adolescents.
Through a series of teleconferences,
electronic communications, and public
discussions during the NVAC meetings,
a working group identified a number of
draft recommendations categorized into
five priority areas of opportunity for
improving vaccination coverage among
adolescents. The draft report and draft
recommendations from the working
group will inform NVAC deliberations
as the NVAC finalizes their
recommendations for transmittal to the
ASH.
On behalf of NVAC, NVPO is
soliciting public comment on the draft
report and draft recommendations from
a variety of stakeholders, including the
general public. Comments will be
considered by the NVAC as it develops
its final recommendations to the ASH.
It is anticipated that the draft report and
draft recommendations, as revised with
consideration given to public comment
and stakeholder input, will be presented
to the NVAC for discussion and
adoption in NVAC meeting in June
2015.
Comments for consideration by
the NVAC should be received no later
than 5:00 p.m. EDT on May 6, 2015.
ADDRESSES:
(1) The draft report and draft
recommendations are available on the
web at https://www.hhs.gov/nvpo/nvac/
subgroups/nvac-hpv-wg.html.
(2) Electronic responses are preferred
and may be addressed to: HPVwg@
hhs.gov.
(3) Written responses should be
addressed to: National Vaccine Program
Office, U.S. Department of Health and
Human Services, 200 Independence
Avenue SW., Room 715H, Washington,
DC 20201. Attn: HHS HPV
Immunizations.
tkelley on DSK4VPTVN1PROD with NOTICES
DATES:
FOR FURTHER INFORMATION CONTACT:
National Vaccine Program Office, Office
of the Assistant Secretary for Health,
Department of Health and Human
VerDate Sep<11>2014
18:14 Apr 03, 2015
Jkt 235001
Services; telephone (202) 690–5566; fax
(202) 690–4631; email: HPVwg@hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
There are an average of 25,900 newly
diagnosed cases per year of human
papillomavirus (HPV)-associated cancer
in the United States. An estimated 14
million people are newly infected with
HPV each year and nearly half of these
infections occur in people between the
ages of 14–25 years. While most
infections resolve over time, persistent
infection with oncogenic HPV types is
associated with a variety of cancers.
Virtually all cervical cancers are due to
HPV along with 90 percent of anal, 69
percent of vaginal, 60 percent of
oropharyngeal, 51 percent of vulvar, and
40 percent of penile cancers. Further, 87
percent of anal, 76 percent of cervical,
60 percent of oropharyngeal, 55 percent
of vaginal, 44 percent of vulva and 29
percent of penile cancers are caused by
oncogenic HPV types 16 or 18. Of the
35,000 HPV cancers reported in 2009 in
the U.S., 39 percent occurred in males.
Through their analysis and
discussion, the NVAC identified five
major areas of opportunity:
(1) Endorsing the President’s Cancer
Panel (PCP) report, Accelerating HPV
Vaccine Uptake: Urgency for Action to
Prevent Cancer, and adopt the
recommendations outlined therein.
(2) Monitoring ‘‘the status of uptake
and implementation of the
recommendations’’ through an annual
progress report from HPV vaccination
stakeholders identified in the PCP
report.
(3) Working with relevant agencies
and stakeholders to develop evidencebased, effective, coordinated
communication strategies to increase
the strength and consistency of clinician
recommendations for HPV vaccination
to adolescents (both males and females)
in the recommended age groups and to
improve acceptance among parents/
guardians, adolescents and young
adults.
(4) Working with the relevant
agencies and stakeholders to strengthen
the immunization system in order to
maximize access to and support of
adolescent vaccinations, including HPV
vaccines.
(5) Encouraging the review or
development of available data that
could lead to a simplified HPV
vaccination schedule. In addition to a
review that could impact existing
vaccines, manufacturers of HPV
vaccines in development should also
consider opportunities to support the
simplest HPV immunization schedule
PO 00000
Frm 00055
Fmt 4703
Sfmt 9990
while maintaining vaccine effectiveness,
safety, and long-term protection.
II. Request for Comment
NVPO, on behalf of the NVAC HPV
Working Group, requests input on the
draft report and draft recommendations.
In addition to general comments on the
draft report and draft recommendations,
NVPO is seeking input on efforts or
barriers to HPV immunization not
represented in the report where HHS
efforts could advance adolescent
immunization efforts. Please limit your
comments to six (6) pages.
III. Potential Responders
HHS invites input from a broad range
of stakeholders including individuals
and organizations that have interests in
HPV immunization efforts and the role
of HHS in advancing those efforts.
Examples of potential responders
include, but are not limited to, the
following:
—General public;
—advocacy groups, non-profit
organizations, and public interest
organizations;
—academics, professional societies, and
healthcare organizations;
—public health officials and
immunization program managers;
—adolescent provider groups including
all physician and non-physician
providers that administer healthcare
services to adolescents, including
pharmacists; and
—representatives from the private
sector.
When responding, please self-identify
with any of the above or other categories
(include all that apply) and your name.
Anonymous submissions will not be
considered. Written submissions should
not exceed six (6) pages. Please do not
send proprietary, commercial, financial,
business, confidential, trade secret, or
personal information.
Dated: March 20, 2015.
Bruce Gellin,
Deputy Assistant Secretary for Health,
Director, National Vaccine Program Office,
Executive Secretary, National Vaccine
Advisory Committee.
[FR Doc. 2015–07777 Filed 4–3–15; 8:45 am]
BILLING CODE 4150–44–P
E:\FR\FM\06APN1.SGM
06APN1
]]>Agencies
[Federal Register Volume 80, Number 65 (Monday, April 6, 2015)]
[Notices]
[Pages 18405-18406]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2015-07777]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Solicitation of Written Comments on the Human Papillomavirus
Working Group's Draft Report and Draft Recommendations for Improving
Vaccination Rates in Adolescents for Consideration by the National
Vaccine Advisory Committee
AGENCY: National Vaccine Program Office, Office of the Assistant
Secretary for Health, Office of the Secretary, Department of Health and
Human Services.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Vaccine Advisory Committee (NVAC) was established
in 1987 to comply with Title XXI of the Public Health Service Act (Pub.
L. 99-660) (Sec. 2105) (42 U.S. Code 300aa-5 (PDF--78 KB)). Its
purpose is to advise and make recommendations to the Director of the
National Vaccine Program on matters related to program
responsibilities. The Assistant Secretary for Health (ASH) has been
designated by the Secretary of Health and Human Services (HHS) as the
Director of the National Vaccine Program. The National Vaccine Program
Office (NVPO) is located within the Office of the Assistant Secretary
for Health (OASH), Office of the Secretary, U.S. Department of Health
and Human Services (HHS). NVPO provides leadership and fosters
collaboration among the various federal
[[Page 18406]]
agencies involved in vaccine and immunization activities. The NVPO also
supports the National Vaccine Advisory Committee (NVAC). The NVAC
advises and makes recommendations to the ASH in her capacity as the
Director of National Vaccine Program on matters related to vaccine
program responsibilities.
In February 2013, the NVAC created a working group to review the
current state of HPV immunization, to understand the root cause(s) for
the observed low vaccine uptake, both in initiation and in series
completion, and to identify existing best practices to increase the use
of the HPV vaccine in young adolescents.
Through a series of teleconferences, electronic communications, and
public discussions during the NVAC meetings, a working group identified
a number of draft recommendations categorized into five priority areas
of opportunity for improving vaccination coverage among adolescents.
The draft report and draft recommendations from the working group will
inform NVAC deliberations as the NVAC finalizes their recommendations
for transmittal to the ASH.
On behalf of NVAC, NVPO is soliciting public comment on the draft
report and draft recommendations from a variety of stakeholders,
including the general public. Comments will be considered by the NVAC
as it develops its final recommendations to the ASH. It is anticipated
that the draft report and draft recommendations, as revised with
consideration given to public comment and stakeholder input, will be
presented to the NVAC for discussion and adoption in NVAC meeting in
June 2015.
DATES: Comments for consideration by the NVAC should be received no
later than 5:00 p.m. EDT on May 6, 2015.
ADDRESSES:
(1) The draft report and draft recommendations are available on the
web at https://www.hhs.gov/nvpo/nvac/subgroups/nvac-hpv-wg.html.
(2) Electronic responses are preferred and may be addressed to:
HPVwg@hhs.gov.
(3) Written responses should be addressed to: National Vaccine
Program Office, U.S. Department of Health and Human Services, 200
Independence Avenue SW., Room 715H, Washington, DC 20201. Attn: HHS HPV
Immunizations.
FOR FURTHER INFORMATION CONTACT: National Vaccine Program Office,
Office of the Assistant Secretary for Health, Department of Health and
Human Services; telephone (202) 690-5566; fax (202) 690-4631; email:
HPVwg@hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
There are an average of 25,900 newly diagnosed cases per year of
human papillomavirus (HPV)-associated cancer in the United States. An
estimated 14 million people are newly infected with HPV each year and
nearly half of these infections occur in people between the ages of 14-
25 years. While most infections resolve over time, persistent infection
with oncogenic HPV types is associated with a variety of cancers.
Virtually all cervical cancers are due to HPV along with 90 percent of
anal, 69 percent of vaginal, 60 percent of oropharyngeal, 51 percent of
vulvar, and 40 percent of penile cancers. Further, 87 percent of anal,
76 percent of cervical, 60 percent of oropharyngeal, 55 percent of
vaginal, 44 percent of vulva and 29 percent of penile cancers are
caused by oncogenic HPV types 16 or 18. Of the 35,000 HPV cancers
reported in 2009 in the U.S., 39 percent occurred in males.
Through their analysis and discussion, the NVAC identified five
major areas of opportunity:
(1) Endorsing the President's Cancer Panel (PCP) report,
Accelerating HPV Vaccine Uptake: Urgency for Action to Prevent Cancer,
and adopt the recommendations outlined therein.
(2) Monitoring ``the status of uptake and implementation of the
recommendations'' through an annual progress report from HPV
vaccination stakeholders identified in the PCP report.
(3) Working with relevant agencies and stakeholders to develop
evidence-based, effective, coordinated communication strategies to
increase the strength and consistency of clinician recommendations for
HPV vaccination to adolescents (both males and females) in the
recommended age groups and to improve acceptance among parents/
guardians, adolescents and young adults.
(4) Working with the relevant agencies and stakeholders to
strengthen the immunization system in order to maximize access to and
support of adolescent vaccinations, including HPV vaccines.
(5) Encouraging the review or development of available data that
could lead to a simplified HPV vaccination schedule. In addition to a
review that could impact existing vaccines, manufacturers of HPV
vaccines in development should also consider opportunities to support
the simplest HPV immunization schedule while maintaining vaccine
effectiveness, safety, and long-term protection.
II. Request for Comment
NVPO, on behalf of the NVAC HPV Working Group, requests input on
the draft report and draft recommendations. In addition to general
comments on the draft report and draft recommendations, NVPO is seeking
input on efforts or barriers to HPV immunization not represented in the
report where HHS efforts could advance adolescent immunization efforts.
Please limit your comments to six (6) pages.
III. Potential Responders
HHS invites input from a broad range of stakeholders including
individuals and organizations that have interests in HPV immunization
efforts and the role of HHS in advancing those efforts.
Examples of potential responders include, but are not limited to,
the following:
--General public;
--advocacy groups, non-profit organizations, and public interest
organizations;
--academics, professional societies, and healthcare organizations;
--public health officials and immunization program managers;
--adolescent provider groups including all physician and non-physician
providers that administer healthcare services to adolescents, including
pharmacists; and
--representatives from the private sector.
When responding, please self-identify with any of the above or
other categories (include all that apply) and your name. Anonymous
submissions will not be considered. Written submissions should not
exceed six (6) pages. Please do not send proprietary, commercial,
financial, business, confidential, trade secret, or personal
information.
Dated: March 20, 2015.
Bruce Gellin,
Deputy Assistant Secretary for Health, Director, National Vaccine
Program Office, Executive Secretary, National Vaccine Advisory
Committee.
[FR Doc. 2015-07777 Filed 4-3-15; 8:45 am]
BILLING CODE 4150-44-P
